GT Biopharma, Inc. (GTBP)

NCM – Real Time Price. Currency in USD

0.43

+0.01 (3.34%)

At close: Jun 26, 2026, 4:00 PM EDT

0.44

+0.01 (1.35%)

After-hours: Jun 26, 2026, 7:53 PM EDT

01.06.2026

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today provided an update on its newly implemented AI-based technological initiatives and improved pipeline discovery efficiencies, which are expected to lead to additional development candidates advancing into pre-IND development in 2027. "We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities," said Michael Breen, Executive Chairman and Chief Executive Officer.

15.05.2026

GT Biopharma Reports First Quarter 2026 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced first quarter 2026 financial results for the period ended March 31, 2026. "With the initiation of our GTB-5550 Phase 1 trial, we have now advanced three TriKE® candidates into the clinic, a significant milestone that underscores the continued momentum of our pipeline," said Michael Breen, Executive Chairman and Chief Executive Officer.

14.05.2026

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GTB-5550 is now the 3rd TriKE ® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company anticipates providing updates in 2H 2026 as enrollment progresses through dose escalation cohorts SAN FRANCISCO, CALIFORNIA, May 14, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluating GTB-5550, its B7-H3-targeted natural killer (NK) cell engager for solid tumors expressing B7-H3. “Dosing the first patient in our GTB-5550 Phase 1 trial is a pivotal milestone for GT Biopharma and represents the natural evolution of our TriKE® platform into the broader opportunity of treating patients with a variety of solid tumors.

14.05.2026

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma Inc. (NASDAQ:GTBP) on Thursday dosed the first patient on a Phase 1 dose-escalation basket trial evaluating GTB-5550, its B7-H3-targeted NK cell engager for solid tumors expressing B7-H3.

16.03.2026

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

12.03.2026

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

02.03.2026

GT Biopharma Reports Full Year 2025 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5

Videos

No Data

There is no data to display

Press releases

01.06.2026

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

15.05.2026

GT Biopharma Reports First Quarter 2026 Financial Results

14.05.2026

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

02.03.2026

GT Biopharma Reports Full Year 2025 Financial Results

Phase 1 trial evaluating GTB-3650 TriKE ® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5

GT Biopharma, Inc. (GTBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

GT Biopharma, Inc. (GTBP)

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma Reports Full Year 2025 Financial Results

Videos

No Data

Press releases

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GT Biopharma Reports Full Year 2025 Financial Results

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma Reports Full Year 2025 Financial Results

Videos

No Data

Press releases

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GT Biopharma Reports Full Year 2025 Financial Results

Search stocks

GT Biopharma, Inc. (GTBP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

GT Biopharma, Inc. (GTBP)

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma Reports Full Year 2025 Financial Results

Videos

No Data

Press releases

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GT Biopharma Reports Full Year 2025 Financial Results

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types

GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

GT Biopharma Reports Full Year 2025 Financial Results

Videos

No Data

Press releases

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma Reports First Quarter 2026 Financial Results

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

GT Biopharma Reports Full Year 2025 Financial Results